Healthcare >> Sector Roundtables >> June 1, 2009

Roundtable Forum: Investing In Biotechnology Stocks

George Huang is a biotechnology analyst at Stansberry & Associates, an independent equity research firm. His coverage universe includes small- to mid- cap biotechs with a strong focus in the infectious diseases, metabolic diseases, autoimmunity, oncology and platform technologies. His research and trading strategies are featured in two publications (The FDA Report, Phase 1 Investor). He was the Pollard Scholar and received his PhD in Cellular and Molecular Medicine from Johns Hopkins University and Bachelor of Science degree in Biology from University of British Columbia. Profile
TWST: Ram, let's start with you. What's the state of the biotech industry?

Dr. Selvaraju: There have obviously been some significant headwinds in the

industry for some time now. Primarily,